Radius Health Inc (NASDAQ:RDUS) has been given a consensus rating of “Hold” by the nine research firms that are presently covering the stock, Marketbeat reports. Six analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $32.60.

Several research analysts recently commented on the stock. HC Wainwright increased their target price on shares of Palatin Technologies from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Thursday, May 9th. Cowen restated a “buy” rating and set a $149.00 target price on shares of Intercept Pharmaceuticals in a report on Wednesday, May 8th. ValuEngine upgraded shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, April 1st. Zacks Investment Research cut shares of GALP ENERGIA SG/ADR from a “hold” rating to a “sell” rating in a report on Monday, May 6th. Finally, Goldman Sachs Group upgraded shares of Koninklijke KPN from a “neutral” rating to a “buy” rating in a report on Wednesday, May 29th.

Shares of Radius Health stock traded up $0.35 on Wednesday, hitting $21.87. The company had a trading volume of 191,404 shares, compared to its average volume of 395,782. The company has a market capitalization of $992.23 million, a price-to-earnings ratio of -4.48 and a beta of 1.06. Radius Health has a twelve month low of $12.81 and a twelve month high of $26.03. The company has a debt-to-equity ratio of 6.75, a current ratio of 5.16 and a quick ratio of 5.04. The company has a 50-day simple moving average of $23.01.

Radius Health (NASDAQ:RDUS) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.95) by $0.01. The company had revenue of $29.84 million during the quarter, compared to analysts’ expectations of $35.35 million. Radius Health had a negative net margin of 176.84% and a negative return on equity of 233.12%. The business’s quarterly revenue was up 105.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.11) earnings per share. As a group, equities analysts predict that Radius Health will post -3.58 EPS for the current fiscal year.

In other Radius Health news, Director Anthony Rosenberg sold 1,584 shares of the stock in a transaction on Monday, July 1st. The shares were sold at an average price of $24.60, for a total value of $38,966.40. Following the completion of the sale, the director now owns 8,716 shares in the company, valued at $214,413.60. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Joseph Francis Kelly purchased 2,000 shares of the business’s stock in a transaction on Friday, May 10th. The stock was purchased at an average price of $21.43 per share, with a total value of $42,860.00. Following the purchase, the vice president now owns 5,000 shares of the company’s stock, valued at $107,150. The disclosure for this purchase can be found here. Corporate insiders own 4.00% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. Xact Kapitalforvaltning AB bought a new stake in Radius Health during the 2nd quarter valued at $225,000. First Trust Advisors LP bought a new stake in Radius Health during the 1st quarter valued at $1,320,000. Marshall Wace LLP bought a new stake in Radius Health during the 1st quarter valued at $371,000. AlphaCrest Capital Management LLC bought a new stake in Radius Health during the 1st quarter valued at $502,000. Finally, DekaBank Deutsche Girozentrale increased its stake in Radius Health by 1,098.7% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 189,400 shares of the biopharmaceutical company’s stock valued at $3,739,000 after purchasing an additional 173,600 shares in the last quarter.

Radius Health Company Profile

Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.

See Also: What is a management fee?

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.